Overview

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of VX-659 in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Ivacaftor
VX-659